Construction of a Multipurpose M13KE Phage Display System

In this study, a multipurpose M13KE phage display vector was constructed from wild-type M13KE phage for long peptide or protein display libraries without helper phage to expand the scope of targeted high-throughput screening. Based on the relationship between the structure and function of minor coat protein of wild-type MI3KE （wt-plII）, a truncated gene III （tglll） encoding minor coat protein from M13KE phage was cloned. A fusion gene fragment harboring a hw/tac promoter, signal peptide and C-terminal region sequence of gill was assembled with SOEing-PCR （splice-overlapping-extension polymerase chain reaction） method and inserted into M13KE vector. SDS-PAGE and Western blot analysis with anti-M13 pIII moneclonal antibody were employed to detect the expression of re- combinant protein, c-Myc and HA tag sequences were fused into the recombinant protein. The results showed that tglll was inserted into an unessential region of M13KE. According to the results of SDS-PAGE and Western blot with anti-M13 pIII antibody, pIII was expressed by wt-gIII and tgIII, glII harboring two tags ex- pressed both c-Myc and HA peptides using SDS-PAGE and Western blot with the corresponding monoclonal antibodies. In this study, a multipurpose M13KE phage display system was successfully constructed, which could express both short and long peptide libraries without helper phage. In future, the obtained M13KE phage display system may be used for targeted high-throughput screening of long peptide libraries without helper phage.

Insights into therapeutic peptides in the cancerimmunity cycle:Update and challenges

Immunotherapies hold immense potential for achieving durable potency and long-term survival opportunities in cancer therapy.As vital biological mediators,peptides with high tissue penetration and superior selectivity offer significant promise for enhancing cancer immunotherapies(CITs).However,physicochemical peptide features such as conformation and stability pose challenges to their on-target efficacy.This review provides a comprehensive overview of recent advancements in therapeutic peptides targeting key steps of the cancer-immunity cycle(CIC),including tumor antigen presentation,immune cell regulation,and immune checkpoint signaling.Particular attention is given to the opportunities and challenges associated with these peptides in boosting CIC within the context of clinical progress.Furthermore,possible future developments in this field are also discussed to provide insights into emerging CITs with robust efficacy and safety profiles.